GuidelineEuropean radiology2025
ESR Essentials: gadolinium-wise MRI-practice recommendations by the European Society for Magnetic Resonance in Medicine and Biology.
Guideline in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rationales for Non-standard GBCA Dosing-Low?-High?-When? and Why?: A Literature-based Study.Investigative radiology · 2026Pooled it
- Use of gadolinium-based contrast agents in head and neck cancer diagnosis, staging, and monitoring: current applications and future perspectives.European radiology · 2026Review
- TargetedImmunotherapy advances · 2026Review
- Hepatic enhancement and signal intensity analysis on magnetic resonance imaging as prognostic biomarkers in advanced chronic liver disease.World journal of hepatology · 2025Article
- Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.Archives of toxicology · 2025Review
- Manganese-Based Contrast Agents as Alternatives to Gadolinium: A Comprehensive Review.Clinics and practice · 2025Review
- Improved target volume delineation for stereotactic radiosurgery in brain metastases using post-contrast 3D T1 TSE black-blood MRI.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Gadolinium Research and Education Committee (GREC) is a working group of the European Society for Magnetic Resonance in Medicine and Biology (ESMRMB), established in 2016. The aim of the committee is to monitor scientific evidence for a continuous quality and safety improvement of enhanced MRI using gadolinium-based contrast agents (GBCAs), and also assess potential alternatives. The scope of the present article is to describe the level of evidence concerning safety beyond the single patient (access to community and environmental impact), justification and optimization of the use of GBCAs beyond dosage (appropriateness and influence on clinical decision making), dose reduction with the use of AI (benefits and pitfalls), the advent of next-generation GBCAs (based on currently available data). CLINICAL RELEVANCE: GBCAs are extensively used in MRI and influence clinical decision-making. Their use to enhance the contrast-to-noise ratio is guided by recommendations from subspecialty societies. These guidelines advocate for GBCA use as an additional tool when necessary, ensuring they are administered at the lowest reasonable dose. KEY POINTS: The choice of GBCAs used in radiology should be based on MRI cost-effectiveness, MRI access to the patient community, and impact on the environment, (evidence level: low). GBCA optimization includes reducing GBCA volume burden and increasing appropriateness by including post-contrast enhancement in MRI protocols, depending on clinical indications, (evidence level: moderate). Next-generation GBCAs show higher kinetic stability and higher T1 relaxivity when compared with standard macrocyclic GBCAs allowing comparable diagnostic accuracy at lower doses, (evidence level: moderate).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.